NasdaqGS - Nasdaq Real Time Price USD

Kamada Ltd. (KMDA)

Compare
5.31 -0.08 (-1.48%)
As of 11:12 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Amir London Chief Executive Officer 611k -- 1969
Mr. Chaime Orlev Chief Financial Officer 387k -- 1970
Mr. Eran Nir Chief Operating Officer 332k -- 1973
Mr. Jon R. Knight Vice President of US Commercial Operations 307k -- 1966
Mr. Boris Gorelik Vice President of Business Development & Strategic Programs 410k -- 1981
Mr. David Tsur Co-Founder & Independent Deputy Chairman of the Board 252k -- 1950
Mr. Nir Livneh B.A., L.L.B. VP, General Counsel & Corporate Secretary -- -- 1980
Ms. Hanni Neheman Vice President of Marketing & Sales -- -- 1970
Ms. Liron Reshef Vice President of Human Resources -- -- 1972
Ms. Shavit Beladev Vice President of Kamada Plasma -- -- --

Kamada Ltd.

2 Holzman Street
Science Park PO Box 4081
Rehovot, 7670402
Israel
972 8 940 6472 https://www.kamada.com
Sector:?
Healthcare
Full Time Employees:?
378

Description

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Corporate Governance

Kamada Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 11, 2024 at 1:30 PM UTC - November 15, 2024 at 1:30 PM UTC

Kamada Ltd. Earnings Date

Recent Events

October 21, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

September 23, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 14, 2024 at 12:30 PM UTC

Q2 2024 Earnings Call

August 14, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 7, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 8, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 1, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 6, 2024 at 12:00 AM UTC

20-F: Periodic Financial Reports

December 28, 2023 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

December 6, 2023 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

Related Tickers